In this clinical conversation, Professor Simon Willcock talks to fellow GP Dr Peter Piazza about his past experience of prescribing the two PBS-listed oral antivirals for Covid-19 and his current approach to treating high-risk patients.

Disclaimers: Professor Willcock has participated in educational and advisory events sponsored by MSD (manufacturers of Lagevrio) and has received payments for doing so. Dr Piazza has received honoraria, travel and accommodation costs from a large number of pharmaceutical companies including MSD and Pfizer.